Organon makes another women’s health move with deal for endometriosis-focused Forendo
Organon’s proposed acquisition of Forendo Pharma is the company’s third since spinning out of Merck in the summer. Clinical-stage Forendo is developing a new, potentially more targeted approach to treating endometriosis.